This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.

Related Posts

HP Enterprise stock outperforms despite revenue miss, Evercore maintains rating

HP Enterprise stock outperforms despite revenue miss, E...

German industrial orders rise more than expected in October

German industrial orders rise more than expected in Oct...

SoFi prices $1.5 billion public offering of common stock

SoFi prices $1.5 billion public offering of common stock

Form 144 Yuanbao Inc. For: 4 December

Form 144 Yuanbao Inc. For: 4 December

Brown Forman stock price target raised to $32 by Evercore ISI

Brown Forman stock price target raised to $32 by Everco...

SoFi’s red-hot stock drops after plan to raise $1.5 billion in stock offering

SoFi’s red-hot stock drops after plan to raise $1.5 bil...